Genomics (NASDAQ:TXG – Free Report) had its price objective trimmed by JPMorgan Chase & Co. from $14.00 to $12.00 in a ...

Genomics (NASDAQ:TXG – Free Report) had its price objective decreased by UBS Group from $20.00 to $14.00 in a research report ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...

Genomics (NASDAQ:TXG – Get Free Report) is projected to announce its earnings results after the market closes on Thursday, February 20th. Analysts expect 10x Genomics to post earnings of ($0.29) per ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...

Analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of 10x Genomics in a research note issued to investors on Thursday, February 13th. Leerink Partnrs analyst P. Souda ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales ...

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported ...

Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...

Leerink Partners cut shares of 10x Genomics (NASDAQ:TXG – Free Report) from an outperform rating to a market perform rating in a report released on Thursday morning, Ratings reports. The firm ...

Genomics (NASDAQ:TXG – Free Report) had its price objective lowered by Canaccord Genuity Group from $20.00 to $18.00 in a ...